⚠️ Unsupported Browser

Your browser is not supported.

The latest version of Safari, Chrome, Firefox, Internet Explorer or Microsoft Edge is required to use this website.

Click the button below to update and we look forward to seeing you soon.

Update now

M&As in pharma and those troublesome human factors

Culture & mindset development 05th September 2023

In a special feature for Pharma Times, Harry Malcolm, Principal Consultant at Rubica, delves into the world of mergers and acquisitions (M&A) and candidly:

  • Discusses the common challenges leading to the frequent failure of M&A endeavors in pharma,
  • Sheds light on the often overlooked “people aspect” of M&As and the far-reaching implications it can have,
  • Offers insights from senior pharma leaders at AstraZeneca, CSL Vifor, and Sobi on the essential components for effectively integrating people in an M&A process
  • Shares practical ideas on how to ensure the ‘people aspect’ of an M&A isn’t neglected

You can take a read of the full article by clicking here.

Related features